Aptus Pharma Reports Strong H1 Performance and Approves Preferential Equity Issue
Aptus Pharma Ltd 路 Outcome 路 21 Oct 2026, 12:30 am
Aptus Pharma Reports Strong H1 Performance and Approves Preferential Equity Issue For the half year ended 30th Sep'26, Aptus Pharma reported standalone revenue from operations of INR 48.92 cr, up 240% YoY from INR 14.38 cr. Profit after tax rose 191% YoY to INR 5.08 cr versus INR 1.75 cr, with half-year EPS at INR 2.96. Shareholders approved a preferential issue of 16.03 lakh equity shares at INR 280 per share (including INR 270 premium), raising INR 44.88 cr, pending BSE in-principle approval. The company targets 46% pan-India geographic coverage by Mar'27.
Original exchange filing (PDF)
More announcements from Aptus Pharma Ltd
- Outcome of Board Meeting - Allotment of Equity Shares on Preferential Basis under Regulation 30 of SEBI LODR Regulations, 2015 路 12 Nov 2026
- Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting for .... 路 06 Nov 2026
- Receipt of In-Principle Approval for Preferential Issue 路 31 Oct 2026
- Transcript for Earning Call for the Quarter and Half Year ended on September 30, 2026 路 30 Oct 2026
- Audio recording of the Earnings Call dated October 26, 2026 路 27 Oct 2026
- Intimation of Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 路 23 Oct 2026
- Intimation of Earnings Call for the quarter and half year ended September 30, 2026 路 26 Oct 2026
- Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company .... 路 21 Oct 2026
